NasdaqGM:OCSPharmaceuticals
Is Positive Privosegtor Phase 2 Optic Neuritis Data Altering The Investment Case For Oculis Holding (OCS)?
Oculis Holding AG recently presented positive Phase 2 ACUITY trial data for its investigational drug Privosegtor in optic neuritis at the North American Neuro-Ophthalmology Society’s 52nd Annual Meeting in Boston, highlighting improvements in low-contrast visual acuity and neuroprotective effects.
As a Platinum Sponsor at this leading neuro-ophthalmology congress, Oculis underscored Privosegtor’s potential as a first-in-class neuroprotective therapy and advanced its PIONEER registrational...